Form 4: CRISPR Therapeutics Executive James R. Kasinger Reports Stock Transactions

James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• On October 13, 2024, James R. Kasinger vested 2,113 restricted stock units (RSUs), each representing one share of CRISPR Therapeutics AG common stock.
• Following the vesting, Kasinger sold 1,089 shares on October 14, 2024, at a price of $46.28 per share to cover tax withholding obligations.
• After these transactions, Kasinger directly owns 62,597 common shares.
• The vesting of the RSUs is part of an award granted on October 13, 2023, which vests in three equal installments annually.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The remaining restricted stock units will vest in two equal installments on October 13, 2025, and October 13, 2026.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, providing insights into management's perspective on the company's value and prospects. These transactions are closely monitored by investors.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units that vest over time, aligning management's interests with those of shareholders.
• Companies like Intellia Therapeutics and Editas Medicine, which are also in the gene editing space, have similar executive compensation structures.
• The sale of shares to cover tax obligations upon vesting is a standard practice among publicly traded companies.

Stakeholder Impact

• The sale of shares by the executive may have a minor impact on the stock price in the short term.
• The vesting of RSUs incentivizes the executive to contribute to the long-term success of the company.

Key Dates